Molecular Pathogenesis of Myeloproliferative Neoplasms Benjamin RollesAnn Mullally Myeloproliferative Neoplasms (P Bose, Section Editor) 07 November 2022 Pages: 319 - 329
Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies Himachandana AtluriYoheved S. GersteinCourtney D. DiNardo Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 24 October 2022 Pages: 275 - 285
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions Emilia ScalzulliIda CarmosinoMassimo Breccia Chronic Myeloid Leukemias (V Oehler, Section Editor) 20 October 2022 Pages: 198 - 205
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies John Joson NgS. Tiong Ong Chronic Myeloid Leukemias (V Oehler, Section Editor) 19 October 2022 Pages: 181 - 197
Circulating Tumor DNA in Lymphoma Swetha KambhampatiJasmine Zain T-Cell and Other Lymphoproliferative Malignancies (R Mesa, Section Editor) 10 October 2022 Pages: 298 - 305
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation Neel S. Bhatt Health Economics (N Khera, Section Editor) 04 October 2022 Pages: 228 - 242
Pediatric Germline Predisposition to Myeloid Neoplasms Christineil ThompsonSydney AriagnoMira A. Kohorst Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 19 September 2022 Pages: 266 - 274
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults Ginna GranrothNandita KheraCecilia Arana Yi Health Economics (R Mesa) Open access 19 September 2022 Pages: 243 - 253
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms Barbara MoraFrancesco Passamonti Myeloproliferative Neoplasms (P Bose, Section Editor) Open access 01 September 2022 Pages: 127 - 139
Value in Myeloma Care: Myth or Reality Evguenia OuchveridzeKatherine BergerGhulam Rehman Mohyuddin Health Economics (N Khera, Section Editor) 30 August 2022 Pages: 206 - 216
Bispecific Antibodies for the Treatment of Multiple Myeloma Scott R. GoldsmithShawn StreeterFahrettin Covut T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) 27 August 2022 Pages: 286 - 297
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms Anmol BaranwalChristopher N. HahnDevendra K. Hiwase Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 20 August 2022 Pages: 254 - 265
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors Julian A. WaksalJohn Mascarenhas Myeloproliferative Neoplasms (P Bose, Section Editor) 19 August 2022 Pages: 140 - 154
Precision Medicine in Myeloid Malignancies: Hype or Hope? Shristi Upadhyay BanskotaNabin KhanalVijaya Raj Bhatt Health Economics (N Khera, Section Editor) 16 August 2022 Pages: 217 - 227
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia Ivan KrecakMarko LucijanicSrdan Verstovsek Myeloproliferative Neoplasms (P Bose, Section Editor) 06 August 2022 Pages: 155 - 169
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication Nur Hezrin ShahrinCarol WadhamSusan Branford Chronic Myeloid Leukemias (V Oehler, Section Editor) Open access 06 August 2022 Pages: 171 - 180
Management of Chronic Myeloid Leukemia in Children and Young Adults Maegan FordMichael MauroNobuko Hijiya Chronic Myeloid Leukemias (V Oehler, Section Editor) Open access 03 August 2022 Pages: 121 - 126
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms Talha BadarTimothy Chlon Germline Predisposition to Myeloid Neoplasms (M Patnaik, Section Editor) 04 July 2022 Pages: 113 - 120
ANKRD26-Related Thrombocytopenia and Predisposition to Myeloid Neoplasms Mia J. SullivanElizabeth L. PalmerJuliana Perez Botero Germline Predisposition to Myeloid Neoplasms (M. Patnaik, Section Editor) 25 June 2022 Pages: 105 - 112
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies Ryan J. StubbinsSophia KorotevLucy A. Godley Germline Predisposition to Myeloid Neoplasms (R. Mesa, Section Editor) 08 June 2022 Pages: 94 - 104
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk Jenna A. FernandezMrinal M. Patnaik Germline Predisposition to Myeloid Neoplasms (R. MESA, SECTION EDITOR) 02 June 2022 Pages: 82 - 93
MRD in ALL: Optimization and Innovations Eric PierceBenjamin MautnerFiras El Chaer ACUTE LYMPHOCYTIC LEUKEMIA (R. MESA, SECTION EDITOR) 26 May 2022 Pages: 69 - 81
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders Alejandro FerrerAbhishek A. MangaonkarMrinal M. Patnaik Germline Predisposition to Myeloid Neoplasms (R Mesa, Section Editor) 07 May 2022 Pages: 61 - 68
Targeting Apoptosis in ALL Wesley M. SmithDaniel R. Reed Acute Lymphocytic Leukemias (F El Chaer and M Keng, Section Editors) 11 May 2022 Pages: 53 - 60
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies Michael RainoneTanya Siddiqi Chronic Lymphocytic Leukemias (N Jain, Section Editor) 13 January 2022 Pages: 39 - 45
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift Sarah A. WallErin StevensUma Borate Health Economics (N Khera, Section Editor) 13 January 2022 Pages: 31 - 38
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia Jennifer L. McNeerKjeld Schmiegelow Acute Lymphocytic Leukemias (M Keng and F El Chaer, Section Editors) 13 January 2022 Pages: 1 - 14
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities Jennifer LloydCatherine J. Lee Health Economics (N Khera, Section Editor) 11 January 2022 Pages: 25 - 30
Myeloproliferative Neoplasms with Monocytosis Erika MorsiaNaseema Gangat Myelodysplastic Syndromes and MPN/MDS Overlap (BL Stein, Section Editor) 13 November 2021 Pages: 46 - 51
Meeting Challenges in the Long-Term Care of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Michael G. DouvasLara L. Riegler Acute Lymphocytic Leukemias (M Keng and FE Chaer) 04 November 2021 Pages: 15 - 24
The Evolving Landscape of Frontline Therapy in Chronic Phase Chronic Myeloid Leukemia (CML) Heather R. WolfeLindsay A. M. Rein Chronic Myeloid Leukemias (MJ Mauro and G Saglio, Section Editors) 18 October 2021 Pages: 448 - 454
Challenges in Chronic Myeloid Leukemia Management in South America Katia B. PagnanoAna Ines VarelaVirginia Abello Polo Chronic Myeloid Leukemias (MJ Mauro and G Saglio, Section Editors) 15 October 2021 Pages: 440 - 447
Future Directions in Chronic Phase CML Treatment Nathalie Javidi-SharifiGabriela Hobbs Chronic Myeloid Leukemias (MJ Mauro and G Saglio, Section Editors) 14 October 2021 Pages: 500 - 508
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions Kelly L. SchoenbeckKathryn E. Flynn Chronic Myeloid Leukemias (MJ Mauro and G Saglio, Section Editors) 14 October 2021 Pages: 491 - 499
Treatment-Free Remission: the New Goal in CML Therapy Ehab AtallahKendra Sweet Chronic Myeloid Leukemias (MJ Mauro and G Saglio, Section Editors) 07 October 2021 Pages: 433 - 439
A Multi-disciplinary Approach to Managing Chronic Myelogenous Leukemia Patients on Oral Anticancer Therapy at a Large Academic Medical Center Angela CanadeoMary FournogerakisFelicia Zook Chronic Myeloid Leukemias (MJ Mauro and G Saglio, Section Editors) 07 October 2021 Pages: 509 - 516
Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia Ahmed AleemAli R. HaqueElizabeth A. Griffiths Acute Lymphocytic Leukemias (M Keng and F El Chaer, Section Editors) 06 October 2021 Pages: 394 - 404
BTK Inhibitors in Chronic Lymphocytic Leukemia Sameh GaballaJavier Pinilla-Ibarz Chronic Lymphocytic Leukemias (N Jain, Section Editor) 02 October 2021 Pages: 422 - 432
Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic Tiziano BarbuiValerio De Stefano Myeloproliferative Neoplasms (BL Stein, Section Editor) 29 September 2021 Pages: 455 - 463
Elevating Twitter-Based Journal Club Discussions by Leveraging a Voice-Based Platform: #HemepathJC Meets Clubhouse Aadil AhmedKamran M. MirzaSanam Loghavi Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor) 29 September 2021 Pages: 418 - 421
Avapritinib in the Treatment of Systemic Mastocytosis: an Update Samantha BelowLaura C. Michaelis Myeloproliferative Neoplasms (BL Stein, Section Editor) 27 September 2021 Pages: 464 - 472
Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials Brady L. Stein Myeloproliferative Neoplasms (BL Stein, Section Editor) 09 September 2021 Pages: 483 - 489
Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia Danielle HammondGuillermo Montalban-Bravo Myelodysplastic Syndromes and MPN/MDS Overlap (M Patnaik, Section Editor) 09 September 2021 Pages: 405 - 417
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera Joan HowGabriela Hobbs Myeloproliferative Neoplasms (BL Stein, Section Editor) 03 September 2021 Pages: 473 - 482
Targeting BCMA in Multiple Myeloma Carlyn Rose TanUrvi A. Shah Multiple Myeloma (P Kapoor, Section Editor) 25 August 2021 Pages: 367 - 383
Acute Lymphoblastic Leukemia and Acute Lymphoblastic Lymphoma: Same Disease Spectrum but Two Distinct Diagnoses Kathryn A. F. KlineMichael E. KallenJennie Y. Law Acute Lymphocytic Leukemias (M Keng and F El Chaer, Section Editors) 21 August 2021 Pages: 384 - 393
Amyloidosis with Cardiac Involvement: Identification, Characterization, and Management Faizi JamalMichael Rosenzweig T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor) Open access 09 June 2021 Pages: 357 - 366
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments Praveen Ramakrishnan GeethakumariDheepthi Perumal RamasamyAnkit Kansagra Health Economics (N Khera, Section Editor) 05 June 2021 Pages: 345 - 356
The Emerging Role of Hematopathologists and Molecular Pathologists in Detection, Monitoring, and Management of Myeloid Neoplasms with Germline Predisposition Rashmi Kanagal-Shamanna Molecular Testing and Diagnostics (J Khoury, Section Editor) 24 May 2021 Pages: 336 - 344
Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy Sara SmallShuo Ma Chronic Lymphocytic Leukemias (N Jain, Section Editor) 22 May 2021 Pages: 325 - 335